Trial Profile
Phase I Trail of pegylated liposomal doxorubicin (PLD) in combination with Irinotecan (CPT-11) in Patients with Platinum Refractory and Resistant Ovarian cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Irinotecan (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 31 Jan 2013 Status changed from recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 02 May 2011 New trial record